Navigation Links
Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Date:2/18/2009

,254 Total Operating Expenses 1,228,342 978,105 Loss From Operations (1,228,342) (971,855) Sale of state income tax loss, net -- -- Other noncash income -- -- Interest income, net 17,994 25,227 Amortization of debt discount and financing costs (106,342) (38,374) Interest expense on convertible notes (307,651) (64,836) Net Loss $(1,624,341) $(1,049,838) Basic and Diluted Net Loss Per Common Share $(0.09) $(0.06) Basic and Diluted Weighted Average Number of Common Shares Outstanding 18,629,575 17,474,870

                                                               From Inception
                                   For the Six    For the Six    on July 1,
                                   Months Ended   Months Ended  1998 through
                                   December 31,   December 31,  December 31,
                                       2008          2007           2008

    Revenue                          $200,000      $377,500     $1,375,000

    Operating Expenses:

      General and administrative    1,178,921       974,910     22,904,377
      Research and development      1,083,672       745,149     11,041,267
    Total Operating Expenses        2,262,593     1,720,059     33,945,644

    Loss From Operations           (2,062,593)   (1,342,559)   (32,570,644)

    Sale of state income tax
     loss, net                             --            --        586,442
    Other noncash income                   --            --        321,259
    Interest income, net               41,051        32,106        521,288
    Amortization of debt
     discount and financing costs    (212,397)     
'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
2. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
3. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
5. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
6. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
7. Senesco Technologies to Present at BIO 2008 Business Forum
8. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics including high value and ... first quarter 2015 financial results will be released ... of market. At 8:30 am Eastern Time, Pfenex management ... financial results and provide a business update. A press ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research ... $4.4 million, compared to $8.0 million during the same period ... was $8.9 million, or $0.23 per basic and diluted share. ... period in 2014, of $8.7 million, or $0.27 per basic ... cash equivalents and investments totaled $117.5 million. , "During ...
(Date:4/30/2015)... & Budapest, Hungary (PRWEB) April 30, 2015 ... web-based electronic lab notebook with integrated protocols and ... providing chemistry software solutions and consulting services for ... to the development of Labguru’s newest feature: chemical ... of deep domain features for biologists, bio-chemists, and ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Nektar Therapeutics,(Nasdaq: NKTR ) announced today that ... NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals,have also ... additional,trials: a randomized Phase 2 study to evaluate NKTR-102 ... gene mutation, and a,Phase 2 study in metastatic breast ...
... - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ... has been granted its 31st U.S. Patent, # ... The patent includes claims to pharmaceutical compositions containing ... our proprietary position for REOLYSIN(R)," said Mary Ann ...
... Support Development of Micromet,s EpCAM-specific Antibody Therapeutics BETHESDA, ... (Nasdaq: MITI ), a biopharmaceutical company ... cancer, inflammation and autoimmune diseases today announced the ... Nature Cell Biology (1) revealing a novel ...
Cached Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 4
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... at high latitudes grow better than their counterparts closer ... The study, published in the February issue of The ... Bergmann,s Rule, the observation that animals tend to be ... Bergmann made his observation about latitude and size in ...
... Centers for Disease Control and Prevention, the U.S. Food and ... and Inspection Service are investigating a multistate outbreak of Salmonella ... University of Iowa confirmed on Monday, Jan. 25, that this ... sickened 187 people in 39 states (one case in Iowa) ...
... Professor of Philosophy at Stevens Institute of Technology, was recently ... 2009 in History of Science by the History of Science ... Letters at Stevens, was co-author of the paper, "After the ... wrote the paper with Angela N. H. Creager, a Professor ...
Cached Biology News:Better food makes high-latitude animals bigger 2Hygienic Lab at U. Iowa first to confirm salmonella in nationwide outbreak 2
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
Biology Products: